retatrutide triple agonist glp-1 gip glucagon phase 2 obesity trial Retatrutide, a GIP, and receptor agonist, for people with type diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, 2 conducted in the USA Retatrutide: How the Triple Agonist
Description
Months later, I continue to use a microdose

Total time: 5-7 minutes including preparation and hold time

Endocrinology (2004) 145:268795

Actual costs vary by location, provider, and insurance
